JMP Securities began coverage on shares of Mast Therapeutics, Inc. (NASDAQ:SVRA) in a research note issued to investors on Monday, September 11th, Marketbeat.com reports. The firm issued an outperform rating and a $20.00 price objective on the stock.
A number of other research analysts also recently weighed in on the stock. Zacks Investment Research upgraded shares of Mast Therapeutics from a hold rating to a buy rating and set a $6.75 price target on the stock in a report on Friday, September 8th. Canaccord Genuity restated a buy rating and set a $18.00 price target on shares of Mast Therapeutics in a report on Monday, July 17th.
Shares of Mast Therapeutics (SVRA) opened at 9.47 on Monday. Mast Therapeutics has a 52-week low of $4.60 and a 52-week high of $43.05. The firm’s market cap is $229.20 million. The stock’s 50 day moving average price is $6.20 and its 200-day moving average price is $6.05.
TRADEMARK VIOLATION NOTICE: This story was first posted by BBNS and is the property of of BBNS. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://baseballnewssource.com/markets/mast-therapeutics-inc-svra-now-covered-by-analysts-at-jmp-securities/1634257.html.
Mast Therapeutics Company Profile
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Receive News & Ratings for Mast Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics Inc. and related companies with our FREE daily email newsletter.